Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Apixaban IR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Apixaban Cross-over | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Apixaban IR | DRUG | immediate release tablet, 10 mg, single dose |
| Apixaban MR1 | DRUG | modified release tablet 1, 10 mg, single dose |
| Apixaban MR2 | DRUG | modified release tablet 2, 10 mg, single dose |
| Apixaban MR3 | DRUG | modified release tablet 3, 10 mg, single dose |
Inclusion Criteria: * Healthy male or female patients * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 Exclusion Criteria: * Any condition possibly affecting drug absorption * History or evidence of abnormal bleeding or clotting disorder
Apixaban IR is an investigational small molecule being developed for the treatment of thrombosis, a condition involving blood clot formation. It is currently in Phase 1 clinical development and has not yet been approved by regulatory authorities.
Apixaban IR is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for the treatment of thrombosis.
Apixaban IR is in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. The drug is being studied for the treatment of thrombosis, a condition involving abnormal blood clot formation.
Apixaban IR has one completed clinical trial, identified as NCT00914641, which was a Phase 1 bioavailability study comparing modified release to immediate release apixaban tablets in healthy volunteers. The trial enrolled 16 participants and was conducted in the United States.
Apixaban IR is a specific formulation of apixaban, an anticoagulant medication. The 'IR' designation indicates an immediate release formulation, which was studied in a Phase 1 bioavailability trial (NCT00914641) comparing it to a modified release version in healthy volunteers.